tiprankstipranks
Advertisement
Advertisement

KROS Stock Latest News

Keros Therapeutics price target lowered to $17 from $20 at BofA
The FlyKeros Therapeutics price target lowered to $17 from $20 at BofA
12d ago
KROS
Hold Rating Maintained as Pipeline Progress Offsets Long-Term Uncertainty; Price Target Reaffirmed at $16
PremiumRatings
Hold Rating Maintained as Pipeline Progress Offsets Long-Term Uncertainty; Price Target Reaffirmed at $16
19d ago
KROS
Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo
PremiumThe Fly
Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo
19d ago
KROS
Keros Therapeutics price target lowered to $23 from $30 at Leerink
PremiumThe Fly
Keros Therapeutics price target lowered to $23 from $30 at Leerink
19d ago
KROS
Keros updates TGF-β pipeline strategy in new presentation
PremiumCompany Announcements
Keros updates TGF-β pipeline strategy in new presentation
20d ago
8K
KROS
Keros Therapeutics reports Q2 EPS ($1.45), consensus ($1.24)
PremiumThe FlyKeros Therapeutics reports Q2 EPS ($1.45), consensus ($1.24)
20d ago
KROS
Keros Therapeutics Earns Milestone Payment for Elritercept Trial
Premium
Company Announcements
Keros Therapeutics Earns Milestone Payment for Elritercept Trial
24d ago
8K
KROS
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
Premium
The Fly
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
24d ago
TAK
KROS
Keros Therapeutics Announces CFO Resignation and Interim Successor
PremiumCompany Announcements
Keros Therapeutics Announces CFO Resignation and Interim Successor
1M ago
8K
KROS
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
PremiumCompany Announcements
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
2M ago
KROS
Keros Therapeutics Appoints Anne Prener to Board
PremiumCompany Announcements
Keros Therapeutics Appoints Anne Prener to Board
2M ago
8K
KROS
Keros Therapeutics Stockholders Approve Directors and Governance Matters
PremiumCompany Announcements
Keros Therapeutics Stockholders Approve Directors and Governance Matters
3M ago
8K
KROS
Keros Therapeutics CEO to Present at Goldman Sachs Conference
PremiumCompany AnnouncementsKeros Therapeutics CEO to Present at Goldman Sachs Conference
3M ago
8K
KROS
Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
Premium
Ratings
Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
3M ago
KROS
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
Premium
Ratings
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
3M ago
KROS
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
PremiumThe Fly
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
3M ago
KROS
Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
PremiumRatings
Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
6M ago
KROS
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
PremiumCompany Announcements
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
6M ago
8K
KROS
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
PremiumThe Fly
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
6M ago
KROS
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
PremiumThe FlyKeros Therapeutics presents additional data from Phase 1 of rinvatercept
6M ago
KROS
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
Premium
Company Announcements
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
6M ago
KROS
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
Premium
The Fly
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
6M ago
KROS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >